Ketoglutaric Acid for Hair Regrowth

Created on 11/12/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Ketoglutaric acid, an energy-cycle compound sold as a dietary supplement and promoted for healthy aging, has not been tested alone for hair in people. Applied topically, it switched resting hair roots into growth in young mice, with a slight opposite effect in old mice. Digestive upset is the clearest side effect, and the calcium form can reduce uptake of some thyroid and antibiotic medicines. Risk is low but incompletely charted. (Full Review)

Protocol

Oral Ca-AKG, 1 g/day
Sustained-release
Dose in the ABLE trial and Rejuvant; no human trial has tested AKG alone for hair
Time of day
Commonly with meals
To limit digestive upset; no study compared timing
Topical α-KG (research only)
32 mM gel, every other day
On mouse skin; no human concentration has been tested
Time to effect
Robust regrowth
By day 39
In mice; no human time course exists
Growth phase onset
Within 7 days
Resting mouse follicles entered active growth
Skin darkening
By day 12
Visible in mice; human hair cycles are far longer

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Active cancer, especially lung adenocarcinoma in men
  • Chronic digestive symptoms or acid-suppressant users
  • Hypercalcemia, for Ca-AKG
  • Alopecia areata, personal history
Key Interactions
  • Quinolone antibiotics (ciprofloxacin – Cipro)
  • Levothyroxine (Synthroid)
  • Tetracycline antibiotics (doxycycline – Doryx MPC)
  • Bisphosphonates (alendronate – Fosamax)
Theoretical (inferred from mechanism)
  • Acid-suppressing drugs (omeprazole)
  • Antacids (magnesium hydroxide)
  • Iron supplements (ferrous sulfate)
  • Calcium and vitamin D supplements
  • Other AKG salts (arginine-AKG)
  • mTOR inhibitors and AMPK activators (rapamycin – sirolimus, metformin)
  • HIF prolyl hydroxylase inhibitors (daprodustat – Jesduvroq)

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal intolerance
  • Low: Alopecia areata susceptibility; palpitations and fainting with arginine-AKG products
  • Speculative: Tumor growth modulation; scalp irritation from topical products

Monitoring

Marker Target Why
Hair density (phototrichogram or standardized hair count) No established target; track change from own baseline Intended effect
Serum calcium 8.6–10.3 mg/dL Safety check: Ca-AKG adds calcium
TSH (levothyroxine users only) 0.4–4.0 mIU/L Safety check: calcium can reduce levothyroxine absorption
Serum AKG No established target; track change from own baseline Confirms uptake

Cadence: Baseline before starting; photographs and hair counts at 3 and 6 months, then every 6–12 months while use continues; serum calcium at 3 months; TSH 6–8 weeks after any change in how Ca-AKG is spaced around levothyroxine

Qualitative Assessment

  • Shedding seen in the shower or brush
  • Width of the hair part and visible scalp under fixed lighting
  • Hair pull test result
  • Scalp comfort with topical products (itch, redness, stinging)
  • Digestive tolerance of oral forms
  • Any new round patches of hair loss